Clinical Trials Browser

Active not recruiting × Adenocarcinoma Of Esophagus × trastuzumab deruxtecan × Clear all

NCT05480384 2026-04-21

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms